These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10203064)

  • 1. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ; Lopez T; Montes R; Bald LN; Fendly BM; Campbell MJ
    Cancer Immunol Immunother; 1999 Feb; 47(6):337-42. PubMed ID: 10203064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
    Cappello P; Triebel F; Iezzi M; Caorsi C; Quaglino E; Lollini PL; Amici A; Di Carlo E; Musiani P; Giovarelli M; Forni G
    Cancer Res; 2003 May; 63(10):2518-25. PubMed ID: 12750275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
    Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
    Ercolini AM; Machiels JP; Chen YC; Slansky JE; Giedlen M; Reilly RT; Jaffee EM
    J Immunol; 2003 Apr; 170(8):4273-80. PubMed ID: 12682262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
    Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
    Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
    J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
    Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
    J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.